Skip to Content
  • Previous Rank248
  • Revenues ($M)$12,273.90
  • Revenue Percent Change7.2%
  • Profits ($M)$2,539.10
  • Profits Percent Change-31.4%
  • Assets ($M)$23,652.60
  • Employees7,300
  • Market Value — as of March 29, 2018 ($M)$57,930.10

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases, and hemophilia. It also makes and sells biosimilars of advanced biologics.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

Michel Vounatsos
CEO Title
Chairman & Chief Executive Officer
Health Care
HQ Location
Cambridge, Mass.
Years on Fortune 500 List9

Biogen Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$12,273.907.2%
Profits ($M)$2,539.10-31.4%
Assets ($M)$23,652.60-
Total Stockholder Equity ($M)$12,612.80-
Market Value — as of March 29, 2018 ($M)$57,930.10-

Profit Ratios

Profit as % of Revenues20.7%
Profits as % of Assets10.7%
Profits as % of Stockholder Equity20.1%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)11.92
EPS % Change (from 2016)-29.6%
EPS % Change (5 year annual rate)15.7%
EPS % Change (10 year annual rate)19.6%

Total Return

Total Return to Investors (2017)21.8%
Total Return to Investors (5 year, annualized)18.7%
Total Return to Investors (10 year, annualized)19.8%